Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M698Revenue (TTM) $M--Net Margin (%)--Altman Z-Score55.0
Enterprise Value $M6.0EPS (TTM) $-0.6Operating Margin %--Piotroski F-Score5
P/E(ttm)--Beneish M-Score-3.7Pre-tax Margin (%)--Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio13.1Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-4.5Current Ratio13.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-50.4Higher Current Ratio y-yY
Dividend Yield %2.3PEG--ROE % (ttm)-58.8Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M135ROIC % (ttm)-215.8Gross Margin Increase y-yN

Gurus Latest Trades with CASC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CASCSeth Klarman 2016-06-30 Buy 0.32%$0.85 - $1.35
($1.13)
$ 1.195%New holding25,000,000
CASCFirst Eagle Investment 2016-06-30 Buy $0.85 - $1.35
($1.13)
$ 1.195%New holding400,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CASC is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CASC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Myers Scott DunsethPresident and CEO 2016-08-17Buy45,000$1.151.74view
Myers Scott DunsethPresident and CEO 2016-06-28Buy62,500$0.846.25view
Venkatesan JayEVP and General Manager 2014-09-23Buy250,000$2-41.5view
BVF PARTNERS L P/IL10% Owner 2013-11-01Buy129,000$1.78-34.27view
BVF PARTNERS L P/IL10% Owner 2013-08-08Buy258,361$1.65-29.09view
BVF PARTNERS L P/IL10% Owner 2013-08-01Buy338,087$1.74-32.76view
BVF PARTNERS L P/IL10% Owner 2013-06-07Buy214,467$1.81-35.36view
Ayer Capital Management, LP10% Owner 2011-06-23Sell28,900$8.74-86.61view
Karan Shashi K.Corporate Controller 2010-09-28Buy5,100$3.41-65.69view
Karan Shashi K.Corporate Controller 2009-08-18Buy5,000$5.07-76.92view

Quarterly/Annual Reports about CASC:

    News about CASC:

    Articles On GuruFocus.com
    Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
    Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Jul 11 2016 
    Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
    Cubist Pharmaceutical - Acutely Aware May 09 2010 

    More From Other Websites
    CASCADIAN THERAPEUTICS, INC. Financials Aug 17 2016
    Cascadian Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 08 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 08 2016
    Cascadian Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Aug 08 2016
    Technical Updates on Industrial Goods Sector Equities on CEMEX, 3M Company, Cascadian Therapeutics,... Jul 18 2016
    Coverage of Top Gainers SAGE Therapeutics, Seagate Technology, and Cascadian Therapeutics Jul 13 2016
    Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 11 2016
    Cascadian Therapeutics Inc. (CASC): Billionaire Seth Klarman’s Baupost Group Reports New Stake Jul 11 2016
    Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Jul 11 2016
    Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of... Jun 29 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2016
    Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of... Jun 29 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jun 28 2016
    Cascadian Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of... Jun 28 2016
    Cascadian Therapeutics (CASC) Jumps: Stock Rises 10.4% Jun 24 2016
    CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 23 2016
    Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings of Common Stock and Series D... Jun 23 2016
    Cascadian Therapeutics Prices $41.8 Million Concurrent Offerings of Common Stock and Series D... Jun 23 2016
    Cascadian Therapeutics Announces Proposed Public Offering Jun 22 2016
    Cascadian Therapeutics Announces Proposed Public Offering Jun 22 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)